Lili Zhou1, Sandipan Bhattacharjee2, C Kent Kwoh3, Daniel C Malone4, Patrick J Tighe5, Gary M Reisfield6, Marion Slack7, Debbie L Wilson8, Wei-Hsuan Lo-Ciganic9. 1. Department of Pharmacy Practice and Science, University of Arizona, Tucson, AZ, USA; University of Arizona Arthritis Center, Tucson, AZ, USA. 2. Health Outcome Division, University of Texas at Austin, Austin, Texas, USA. 3. University of Arizona Arthritis Center, Tucson, AZ, USA; Department of Medicine, University of Arizona, Tucson, AZ, USA. 4. Department of Pharmacotherapy, University of Utah, Salt Lake City, UT, USA. 5. Department of Anesthesiology, University of Florida, Gainesville, FL, USA. 6. Divisions of Addiction Medicine & Forensic Psychiatry, Departments of Psychiatry & Anesthesiology, University of Florida, Gainesville, FL, USA. 7. Department of Pharmacy Practice and Science, University of Arizona, Tucson, AZ, USA. 8. Department of Pharmaceutical Outcomes and Policy, University of Florida, Gainesville, FL, USA. 9. Department of Pharmaceutical Outcomes and Policy, University of Florida, Gainesville, FL, USA; Center for Drug Evaluation and Safety, University of Florida, Gainesville, FL, USA. Electronic address: wlociganic@cop.ufl.edu.
Abstract
OBJECTIVES: Little is known about relationships between opioid- and gabapentinoid-use patterns and healthcare expenditures that may be affected by pain management and risk of adverse outcomes. This study examined the association between patients' opioid and gabapentinoid prescription filling/refilling trajectories and direct medical expenditures in US Medicare. METHODS: This cross-sectional study included a 5% national sample (2011-2016) of fee-for-service beneficiaries with fibromyalgia, low back pain, neuropathy, or osteoarthritis newly initiating opioids or gabapentinoids. Using group-based multitrajectory modeling, this study identified patients' distinct opioid and gabapentinoid (OPI-GABA) dose and duration patterns, based on standardized daily doses, within a year of initiating opioids and/or gabapentinoids. Concurrent direct medical expenditures within the same year were estimated using inverse probability of treatment weighted multivariable generalized linear regression, adjusting for sociodemographic and health status factors. RESULTS: Among 67 827 eligible beneficiaries (mean age ± SD = 63.6 ± 14.8 years, female = 65.8%, white = 77.1%), 11 distinct trajectories were identified (3 opioid-only, 4 gabapentinoid-only, and 4 concurrent OPI-GABA trajectories). Compared with opioid-only early discontinuers ($13 830, 95% confidence interval = $13 643-14 019), gabapentinoid-only early discontinuers and consistent low-dose and moderate-dose gabapentinoid-only users were associated with 11% to 23% lower health expenditures (adjusted mean expenditure = $10 607-$11 713). Consistent low-dose opioid-only users, consistent high-dose opioid-only users, consistent low-dose OPI-GABA users, consistent low-dose opioid and high-dose gabapentinoid users, and consistent high-dose opioid and moderate-dose gabapentinoid users were associated with 14% to 106% higher healthcare expenditures (adjusted mean expenditure = $15 721-$28 464). CONCLUSIONS: Dose and duration patterns of concurrent OPI-GABA varied substantially among fee-for-service Medicare beneficiaries. Consistent opioid-only users and all concurrent OPI-GABA users were associated with higher healthcare expenditures compared to opioid-only discontinuers.
OBJECTIVES: Little is known about relationships between opioid- and gabapentinoid-use patterns and healthcare expenditures that may be affected by pain management and risk of adverse outcomes. This study examined the association between patients' opioid and gabapentinoid prescription filling/refilling trajectories and direct medical expenditures in US Medicare. METHODS: This cross-sectional study included a 5% national sample (2011-2016) of fee-for-service beneficiaries with fibromyalgia, low back pain, neuropathy, or osteoarthritis newly initiating opioids or gabapentinoids. Using group-based multitrajectory modeling, this study identified patients' distinct opioid and gabapentinoid (OPI-GABA) dose and duration patterns, based on standardized daily doses, within a year of initiating opioids and/or gabapentinoids. Concurrent direct medical expenditures within the same year were estimated using inverse probability of treatment weighted multivariable generalized linear regression, adjusting for sociodemographic and health status factors. RESULTS: Among 67 827 eligible beneficiaries (mean age ± SD = 63.6 ± 14.8 years, female = 65.8%, white = 77.1%), 11 distinct trajectories were identified (3 opioid-only, 4 gabapentinoid-only, and 4 concurrent OPI-GABA trajectories). Compared with opioid-only early discontinuers ($13 830, 95% confidence interval = $13 643-14 019), gabapentinoid-only early discontinuers and consistent low-dose and moderate-dose gabapentinoid-only users were associated with 11% to 23% lower health expenditures (adjusted mean expenditure = $10 607-$11 713). Consistent low-dose opioid-only users, consistent high-dose opioid-only users, consistent low-dose OPI-GABA users, consistent low-dose opioid and high-dose gabapentinoid users, and consistent high-dose opioid and moderate-dose gabapentinoid users were associated with 14% to 106% higher healthcare expenditures (adjusted mean expenditure = $15 721-$28 464). CONCLUSIONS: Dose and duration patterns of concurrent OPI-GABA varied substantially among fee-for-service Medicare beneficiaries. Consistent opioid-only users and all concurrent OPI-GABA users were associated with higher healthcare expenditures compared to opioid-only discontinuers.
Authors: Jay M Margolis; Zhun Cao; Eberechukwu Onukwugha; Robert J Sanchez; Jose Alvir; Ashish V Joshi; C Daniel Mullins Journal: Am J Manag Care Date: 2010-06 Impact factor: 2.229
Authors: Oliver Enke; Heather A New; Charles H New; Stephanie Mathieson; Andrew J McLachlan; Jane Latimer; Christopher G Maher; C-W Christine Lin Journal: CMAJ Date: 2018-07-03 Impact factor: 8.262
Authors: Kate M Dunn; Kathleen W Saunders; Carolyn M Rutter; Caleb J Banta-Green; Joseph O Merrill; Mark D Sullivan; Constance M Weisner; Michael J Silverberg; Cynthia I Campbell; Bruce M Psaty; Michael Von Korff Journal: Ann Intern Med Date: 2010-01-19 Impact factor: 25.391
Authors: Joseph Pergolizzi; Rainer H Böger; Keith Budd; Albert Dahan; Serdar Erdine; Guy Hans; Hans-Georg Kress; Richard Langford; Rudolf Likar; Robert B Raffa; Paola Sacerdote Journal: Pain Pract Date: 2008-05-23 Impact factor: 3.183
Authors: Wei-Hsuan Lo-Ciganic; Walid F Gellad; Adam J Gordon; Gerald Cochran; Michael A Zemaitis; Terri Cathers; David Kelley; Julie M Donohue Journal: Addiction Date: 2016-01-30 Impact factor: 6.526
Authors: Katherine E Mues; Alexander Liede; Jiannong Liu; James B Wetmore; Rebecca Zaha; Brian D Bradbury; Allan J Collins; David T Gilbertson Journal: Clin Epidemiol Date: 2017-05-09 Impact factor: 4.790